HEART FAILURE
AT CROSSROADS
Bergamo (Italy), November 27th - 29th, 2014
Organized by
CLINICAL RESEARCH FOUNDATION, BERGAMO HOSPITAL (FROM)
AZIENDA OSPEDALIERA PAPA GIOVANNI XXIII - BERGAMO
Promoted by
Under the Auspice of
FIC – Italian Federation of Cardiology
FINAL PROGRAM
Teatro Sociale
Via Colleoni, 4 - Bergamo
HEART FAILURE
AT CROSSROADS
Bergamo (Italy), November 27th - 29th, 2014
Organized by
CLINICAL RESEARCH FOUNDATION, BERGAMO HOSPITAL (FROM)
AZIENDA OSPEDALIERA PAPA GIOVANNI XXIII - BERGAMO
Promoted by
Under the Auspice of
FIC – Italian Federation of Cardiology
FINAL PROGRAM
Teatro Sociale
Via Colleoni, 4 - Bergamo
Heart Failure (HF) is a global pandemic affecting an estimated 26
million people worldwide and resulting in millions of hospitalizations globally. Although the outcomes for ambulatory HF patients with a reduced ejection fraction have improved with the discovery of multiple evidence-based
drug and device therapies, worsening HF patients continue to experience unacceptably high mortality and readmission rates that have not changed in the
last two decades. It is important to note that half of patients with worsening
HF have preserved ejection fraction and have similarly high event-rates for
whom there are no evidence-based therapies to improve outcomes. HF registries have significantly improved our understanding of this clinical entity
and remain an important source of data shaping both public policy and research efforts. Therefore, it is of utmost importance to re-evaluate what is
known, identify what is not known, and develop a roadmap for the improving
outcomes through better understanding of the disease process in order to
identify unique targets for different HF populations. It is essential to “find
the disease” within HF. The typical example is Diabetes, where worsening
HF develops on a different myocardial substrate characterized by specific
myocardial metabolic, functional, neurohormonal and hemodynamic
changes, may respond differently to certain HF therapies and shows unacceptably high morbidity and mortality rates compared to HF without DM.
One-size fits all approach is doubtful to lead to a substantial improvement in
outcomes. The goals of this meeting will be to discuss and summarize current
status of HF and to develop a roadmap for clinical practice and research.
Bergamo has a longstanding tradition in cardiovascular research and
in the new Hospital Papa Giovanni XXIII a research Center devoted to HF
has been established. For these reasons Bergamo represents a perfect location for an update on HF programs.
Antonello Gavazzi, Mihai Gheorghiade, Michele Senni
Course Meeting Directors
–2–
Under the Auspice of
FIC – Italian Federation of Cardiology
Antonello Gavazzi
FROM
Foundation for Research
Bergamo, I
Course Meeting Directors
Michele Senni
Cardiologia 1 - Scompenso e
Trapianti di Cuore
Azienda Ospedaliera
Papa Giovanni XXIII
Bergamo, I
Mihai Gheorghiade
Experimental Therapeutics,
Center for Cardiovascular
Innovation Northwestern
University Feinberg
School of Medicine
Chicago, USA
Scientific Secretary
Marilisa Ambrosio
Azienda Ospedaliera Papa Giovanni XXIII
Bergamo, I
Fumiko Inoue
Project Organizer
Logica Med
Promoted by
Fondazione Internazionale Menarini
Edificio L – Strada 6
Centro Direzionale Milanofiori
I-20089 Rozzano (Milan, Italy)
Phone: +39 02 55308110
Fax: +39 02 55305739
E-mail: milan@fondazione-menarini.it
Http://www.fondazione-menarini.it
Organizing Secretariat
Servizi C.E.C. S.r.l.
Via Verdi, 18
I-24121 Bergamo (Italy)
Phone: +39 035 249899
Provider ECM
MZ Congressi S.r.l.
Provider accreditato n. 966
Via Carlo Farini, 81
I-20159 Milan (Italy)
Phone: +39 02 66802323
–3–
Thursday, November 27th, 2014 – Afternoon
04.00 p.m. - 05.00 p.m. Saluti di Benvenuto / Welcome Addresses
Alessandro Casini, President of “Fondazione
Internazionale Menarini”
Carlo Nicora, General Director, “Ospedale Papa
Giovanni XXIII”, Bergamo
Tiziano Barbui, Scientific Director, FROM
Fondazione per la Ricerca,
Ospedale Papa Giovanni XXIII, Bergamo
Antonello Gavazzi, FROM Fondazione per la
Ricerca, Ospedale Papa Giovanni XXIII,
Bergamo
Michele Senni, Cardiologia 1 – Scompenso e
Trapianti di Cuore,
Ospedale Papa Giovanni XXIII, Bergamo
05.00 p.m. - 06.00 p.m. Lettura Magistrale / Keynote Address
Mihai Gheorghiade
Heart Failure Research over the last 10 years:
the Last Unconquered Frontier in Cardiology
06.00 p.m. - 06.30 p.m. Question and answers Discussion
06.30 p.m. - 08.00 p.m. Tavola rotonda sui “Network di Patologia” /
Round Table on “Pathology Networks”
Mihai Gheorghiade, Michele Senni,
Antonello Gavazzi, Tiziano Barbui
–4–
Friday, November 28th, 2014 – Morning
Session I:
Worsening Heart Failure
08.30 a.m. - 08.45 a.m.
Claudia Vittori
Case Presentation
Discussant: Michele Emdin
Chairpersons:
08.45 a.m. - 09.00 a.m.
09.00 a.m. - 09.15 a.m.
09.15 a.m. - 09.30 a.m.
09.30 a.m. - 10.00 a.m.
10.00 a.m. - 10.30 a.m.
Andrea Di Lenarda
Giuseppe Ambrosio
Javed Butler
What is worsening heart failure? Definition,
epidemiology and classification
Mihai Gheorghiade
Worsening chronic heart failure: end stage disease
or salvageable?
Aldo Pietro Maggioni
Worsening hospitalized heart failure: finally a
surrogate marker among hospitalized heart failure
patients?
Discussion
Coffee break
–5–
Friday, November 28th, 2014 – Morning
Session II:
New Target - New Therapies
10.30 a.m. - 10.45 a.m.
Emilia D’Elia
Case presentation
Discussant: Elisabeth K. Krainer
Chairpersons:
10.45 a.m. - 11.00 a.m.
11.00 a.m. - 11.15 a.m.
11.15 a.m. - 11.30 a.m.
11.30 a.m. - 12.00 a.m.
Giuseppe Di Tano
Maurizio Porcu
Adrian Voors
Targets to develop novel heart failure therapies –
returning to the heart
Javier Diez
The next decade of trials and therapies for heart
failure with reduced ejection fraction
Marco Metra
Hospitalized heart failure: acute therapies, chronic
therapies, or bridging therapies?
Discussion
12.00 a.m. - 02.00 p.m. Lunch
–6–
Friday, November 28th, 2014 – Afternoon
Session III:
Chairpersons:
Beyond Drugs – Alternative Therapeutics
Options
Luca Ferdinando Lorini
Fabrizio Oliva
02.00 p.m. - 02.15 p.m. Attilio Iacovoni
Case presentation
Discussant: Francesco Grigioni
02.15 p.m. - 02.30 p.m. Andrea Mortara
Ambulatory monitoring – options and outcomes
02.30 p.m. - 02.45 p.m. Gaetano Maria De Ferrari
The future of stem cell therapy for heart failure
02.45 p.m. - 03.00 p.m. Maria Frigerio
Circulatory support future
03.00 p.m. - 03.15 p.m. Alec Vahanian
MitraClip
03.15 p.m. - 03.45 p.m. Discussion
03.45 p.m. - 04.15 p.m. Coffee break
–7–
Friday, November 28th, 2014 – Afternoon
Session IV:
Chairpersons:
Heart Failure with preserved ejection fraction:
New directions
Massimo Volpe
Nadia Aspromonte
04.15 p.m. – 04.30 p.m. Michele Senni
Lessons learned from heart failure with preserved
ejection fraction trials
04.30 p.m. - 04.45 p.m. Burkert Mathias Pieske
Next Steps: Outpatient versus Hospitalized patient
04.45 p.m. – 05.15 p.m. Mauro Gori, Aurelia Grosu
Cases presentation
Discussant: Marco Guazzi, Javier Diez
05.15 p.m. – 06.30 p.m. Questions and answers Discussion
–8–
Saturday, November 29th, 2014 – Morning
Session V:
Chairpersons:
HF in patients with Diabetes Mellitus: a
distinct entity
Cheuk-Man Yu
Naoki Sato
08.00 p.m. – 08.15 a.m. Alice Calabrese
Case presentation
Discussant: Renata De Maria
08.15 p.m. – 08.30 a.m. Alessandra Dei Cas
Epidemiology and significance
08.30 a.m. – 08.45 a.m. Giovanni Cioffi
Pathophysiology of heart failure with diabetes
mellitus
08.45 a.m. – 09.00 a.m. Ovidiu Chioncel
The role of kidney in patients with diabetes
mellitus and heart failure
09.00 a.m. – 09.15 a.m. Roberto Trevisan
Treatment of diabetes mellitus in patients with
heart failure
09.15 a.m. – 09.30 a.m. Frank Edelmann
Treatment of heart failure in patients with
diabetes mellitus and future directions
09.30 a.m. – 10.15 a.m.
10.15 a.m. – 10.30 a.m.
Discussion
Coffee break
–9–
Saturday, November 29th, 2014 – Morning
Session VI:
Chairpersons:
Workshop: clinical trials and future directions
Savina Nodari
Mihai Gheorghiade
10.30 a.m. – 10.45 a.m. Robert O. Bonow
Lessons learned from past heart failure trials
10.45 a.m. – 11.00 a.m. Mihai Gheorghiade
Proof of concepts study – from animal models to
human models and the role of T1 centers
11.00 a.m. – 11.15 a.m. Antonello Gavazzi
Matching the drug with the right patients
population
11.15 a.m. – 11.30 a.m. Luigi Tavazzi
What are the appropriate endpoints for heart
failure trials
11.30 a.m. – 11.45 a.m. Cheuk-Man Yu
Trial execution enrollment, retention
11.45 a.m. – 12.45 p.m. Lessons from Registries: Andrew Ambrosy,
Ovidiu Chioncel, Naoki Sato, Luigi Tavazzi
Globalization of heart failure trials: good or bad?
12.45 p.m. – 01.45 p.m. Discussion
01.45 p.m. – 02.05 p.m. Conclusion and Future Directions
Antonello Gavazzi, Mihai Gheorghiade,
Michele Senni
02.05 p.m. – 03.35 p.m. CME/ECM questionnaires
– 10 –
GENERAL INFORMATION
Meeting venue
The venue for the Meeting will be Teatro Sociale, Via Colleoni, 4,
Bergamo (Italy).
Secretariat during the Meeting
The Secretariat will be open at the following times:
Thursday, November 27th, from 03.30 p.m. to 08.00 p.m.
Friday, November 28th, from 08.00 a.m. to 06.30 p.m.
Saturday, November 29th, from 08.00 a.m. to 12.30 a.m.
Official language
The official language of the Meeting will be English.
Registration
The Meeting is free to attend. Please confirm the participation to (Fondazione
Internazionale Menarini, Phone: +39 02 55308110 - Fax: +39 02 55305739 E-mail: milan@fondazione-menarini.it).
Italian CME Accreditation
The application for CME accreditation has been submitted with 8,5 credits for
Italian Physicians and Pharmacist (Cardiology, Pharmacy, General Medicine).
The CME credits will be recognized only after full attendance of all sessions and a
minimum score of 75% of correct answers in the learning questionnaires. Completion of the Registration Form, the Learning & Assessment questionnaires are compulsory.
For information on European Accreditation, please see next page
An application has been made to the EBAC for CME accreditation of this event.
Technical facilities
Facilities will be available for computer presentations and overhead projections. A
business center with PC (Powerpoint for Windows) will be available for check and
preview of presentations. It is essential that speakers take their presentation to the
technicians at least one hour before the session starts.
The center will be open at the following times:
Thursday, November 27th, from 03.30 p.m. to 08.00 p.m.
Friday, November 28th, from 08.00 a.m. to 06.30 p.m.
Saturday, November 29th, from 08.00 a.m. to 12.30 a.m.
Lunch and coffee breaks
Lunch and coffee breaks will be served at Restaurant “Colleoni e dell’Angelo”,
walking distance to the congress venue.
Abstracts book
Participants will receive the Abstracts book at the Meeting.
Certificate of attendance
The certificate of attendance will be available on request at the end of the Meeting
at the Secretariat.
– 11 –
EBAC ACCREDITATION
The event HEART FAILURE AT CROSSROADS is accredited
by the European Board for Accreditation in Cardiology (EBAC)
for 11 hours of External CME credits (Day #1: 0 CME credits
- Day #2: 6 CME credits - Day #3: 5 CME credits).
Each participant should claim only those hours of credit that have actually been
spent in the educational activity. EBAC works according to the quality standards of
the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists
(UEMS).
In compliance with EBAC/ EACCME guidelines, all speakers/ chairpersons participating in this programme have disclosed or indicated potential conflicts of interest
which might cause a bias in the presentations. The Organizing Committee is responsible for ensuring that all potential conflicts of interest relevant to the event are
declared to the audience prior to the CME activities.
Educational objectives:
The goals of this meeting will be to discuss and summarize current status of Heart
Failure and to develop a roadmap for clinical practice and research.
Determination of educational needs:
Worsening HF patients continue to experience unacceptably high mortality and
readmission rates that have not changed in recent years. Therefore, it is of utmost
importance to re-evaluate what is known, identify what is not known, and develop
a roadmap for the improving outcomes through better understanding of the disease
process in order to identify unique targets for different HF populations.
Target audience: Trained cardiologists, Cardiologists in training
CME PROVIDER
Azienda Ospedaliera Papa Giovanni XXIII
COURSE MEETING DIRECTOR
Michele Senni
– 12 –
LIST OF SPEAKERS, DISCUSSANTS, CHAIRPERSONS AND
CO-PRESIDENTS OF THE MEETING
Giuseppe Ambrosio
Cattedra di Cardiologia
Università di Perugia
Ospedale S. Maria della Misericordia
Perugia (Italy)
Marilisa Ambrosio
Segreteria Scientifica
Dipartimento Cardiovascolare
Azienda Ospedaliera Papa Giovanni XXIII
Bergamo (Italy)
Andrew Ambrosy
Division of Cardiology
Duke University Medical Center
Durham, NC (USA)
Nadia Aspromonte
Azienda Complesso Ospedaliero
S. Filippo Neri
Rome (Italy)
Tiziano Barbui
FROM Fondazione per la Ricerca
Ospedale Papa Giovanni XXIII
Bergamo (Italy)
Robert O. Bonow
Center for Cardiovascular Innovation
Northwestern University Feinberg School of Medicine
Northwestern Memorial Hospital
Chicago, IL (USA)
Javed Butler
Division of Cardiology
Emory University School of Medicine
Atlanta (USA)
– 13 –
Alice Calabrese
Cardiologia 1 - Scompenso e Trapianti di Cuore
Azienda Ospedaliera Papa Giovanni XXIII
Bergamo (Italy)
Ovidiu Chioncel
ICCU and Cardiology 1 Department
Heart Transplant Program
Institute of Emergency for Cardiovascular Diseases C.C. Iliescu
Bucharest (Romania)
Giovanni Cioffi
Cardiologia
Villa Bianca Trento
Trento (Italy)
Emilia D’Elia
Cardiologia 1 - Scompenso e Trapianti di Cuore
Azienda Ospedaliera Papa Giovanni XXIII
Bergamo (Italy)
Gaetano Maria De Ferrari
Dipartimento Cardiotoracovascolare
IRCCS Policlinico San Matteo
Pavia (Italy)
Renata De Maria
Dipartimento Cardiotoracovascolare "A. De Gasperis"
Istituto di Fisiologia Clinica del C.N.R.
A.O. Ospedale Niguarda Ca' Granda
Milan (Italy)
Alessandra Dei Cas
Dipartimento di Medicina Clinica e Sperimentale
Università di Parma
Parma (Italy)
Andrea Di Lenarda
Centro Cardiovascolare
ASS1 Triestina
Trieste (Italy)
Giuseppe Di Tano
Cardiologia
Azienda Ospedaliera “Istituti Ospitalieri” di Cremona
Cremona (Italy)
– 14 –
Javier Díez
Department of Cardiology and Cardiac Surgery
Centre for Applied Medical Research
University of Navarra
Pamplona (Spain)
Frank Edelmann
Innere Medizin, Kardiologie, Sportmedizin
University TS Medizin
Göttingen (Germany)
Michele Emdin
Cardiologia e Medicina Cardiovascolare
Fondazione Toscana Gabriele Monasterio
CNR-Regione Toscana
Pisa (Italy)
Maria Frigerio
Cardiologia 2 - Insufficienza Cardiaca e Trapianto
Dipartimento Cardiotoracovascolare "A. De Gasperis"
A.O. Ospedale Niguarda-Ca' Granda
Milan (Italy)
Antonello Gavazzi
FROM Fondazione per la Ricerca
Ospedale Papa Giovanni XXIII
Bergamo (Italy)
Mihai Gheorghiade
Division of Cardiology
Center for Cardiovascular Quality and Outcomes
Northwestern University Feinberg School of Medicine
Chicago, IL (USA)
Mauro Gori
Cardiologia 1 - Scompenso e Trapianti di Cuore
Azienda Ospedaliera Papa Giovanni XXIII
Bergamo (Italy)
Francesco Grigioni
Cardiologia Ospedale S. Orsola
Università degli Studi di Bologna
Bologna (Italy)
– 15 –
Aurelia Grosu
Cardiologia 1 - Scompenso e Trapianti di Cuore
Azienda Ospedaliera Papa Giovanni XXIII
Bergamo (Italy)
Marco Guazzi
Heart Failure Unit
Università di Milano
IRCCS Policlinico San Donato
Milan (Italy)
Attilio Iacovoni
Cardiologia 1 - Scompenso e Trapianti di Cuore
Azienda Ospedaliera Papa Giovanni XXIII
Bergamo (Italy)
Fumiko Inoue
Project Organizer
Logica Med
Elisabeth K. Krainer
Department of Cardiology
University of Graz & Ludwig - Boltzmann
Institute for Translational Heart Failure
Graz (Austria)
Luca Ferdinando Lorini
Anestesia e Rianimazione
Azienda Ospedaliera Papa Giovanni XXIII
Bergamo (Italy)
Aldo Pietro Maggioni
ANMCO Research Centre
Florence (Italy)
Marco Metra
Cattedra di Cardiologia
Spedali Civili e Università di Brescia
Brescia (Italy)
Andrea Mortara
Cardiologia Clinica
Unità dello Scompenso e Terapia Intensiva
Policlinico di Monza
Monza (Italy)
– 16 –
Carlo Nicora
Direzione Generale
Azienda Ospedaliera Papa Giovanni XXIII
Bergamo (Italy)
Savina Nodari
Cattedra di Cardiologia
Spedali Civili e Università di Brescia
Brescia (Italy)
Fabrizio Oliva
Dipartimento Cardiotoracovascolare "A De Gasperis"
A.O. Ospedale Niguarda Ca' Granda
Milan (Italy)
Burkert Mathias Pieske
Department of Cardiology
University Heart Center
Medical University Graz
Graz (Austria)
Maurizio Porcu
Cardiologia
Dipartimento Cardio-Toraco-Vascolare
Azienda Ospedaliera "G. Brotzu" - San Michele
Cagliari (Italy)
Naoki Sato
Internal Medicine and Cardiology
Intensive Care Medicine
Nippon Medical School Musashi-Kosugi Hospital
Kanagawa (Japan)
Michele Senni
Cardiologia 1 - Scompenso e Trapianti di Cuore
Azienda Ospedaliera Papa Giovanni XXIII
Bergamo (Italy)
Luigi Tavazzi
Direzione Scientifica GVM Care & Research
Maria Cecilia Hospital
Cotignola, Ravenna (Italy)
– 17 –
Roberto Trevisan
Unità Malattie Endocrine - Diabetologia
Azienda Ospedaliera Papa Giovanni XXIII
Bergamo (Italy)
Cheuk-Man Yu
Division of Cardiology
Department of Medicine and Therapeutics
The Chinese University of Hong Kong
Hong Kong (China)
Alec Vahanian
Cardiology Department
Hôpital Bichat
Paris (France)
Claudia Vittori
Cardiologia 1 - Scompenso e Trapianti di Cuore
Azienda Ospedaliera Papa Giovanni XXIII
Bergamo (Italy)
Massimo Volpe
Divisione di Cardiologia
Dipartimento di Medicina Clinica e Molecolare
Ospedale Sant'Andrea e Università La Sapienza di Roma
Rome (Italy)
Adrian A. Voors
Department of Cardiology
University Medical Center Groningen
Groningen (The Netherlands)
A Special Thank to
A. Menarini I.F.R.
for not conditioning financial support
– 18 –
NOTES
– 19 –
Menarini Foundation Symposia: 254